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 Abstract 
 Background: Cerebrospinal fluid (CSF) levels assessment 
of A β 
1-42
 and Tau proteins may be accurate diagnostic bio-
markers for the differentiation of preclinical Alzheimer ’ s 
disease (AD) from age-associated memory impairment, 
depression and other forms of dementia in patients with 
mild cognitive impairment (MCI). The aim of our study 
was to explore the utility of CSF biomarkers in combina-
tion with common cognitive markers as predictors for the 
risk of AD development, and other forms of dementia, and 
the time to conversion in community patients with MCI. 
 Methods: A group of 71 MCI patients underwent neuro-
logical assessment, extended neuropsychological evalua-
tion, routine blood tests, ApoE determination, and lumbar 
puncture to dose t-tau, p-tau 
181
 , A β 
1-42
 . We investigated 
baseline CSF and neuropsychological biomarker patterns 
according to groups stratified with later diagnoses of AD 
conversion (MCI-AD), other dementia (MCI-NAD) conver-
sion, or clinical stability (sMCI). 
 Results: Baseline A β 
1-42
 CSF levels were significantly lower 
in MCI-AD patients compared to both sMCI and MCI-NAD. 
Additionally, p-tau 
181
 was higher in the MCI-AD group com-
pared to sMCI. The MCI-AD subgroup analysis confirmed 
the role of A β 
1-42
 in its predictive role of time to conver-
sion: rapid converters had lower A β 
1-42
 levels compared to 
slow converters. Logistic regression and survival analysis 
further supported the key predictive role of baseline A β 
1-42
 
for incipient AD and dementia-free survival. 
 Conclusions: Our results confirm the key role of CSF bio-
markers in predicting patient conversion from MCI to 
dementia. The study suggests that CSF biomarkers may 
also be reliable in a real world clinical setting. 
 Keywords:  Alzheimer ’ s disease;  biomarkers;  cerebrospi-
nal fluid;  mild cognitive impairment. 
 Introduction 
 Alzheimer ’ s disease (AD) is a chronically progressive neu-
rodegenerative disease and the most common form of 
dementia in the elderly. It is well known that AD patho-
logical processes appear gradually and begin to develop 
decades before the onset of clinical symptoms, with 
dementia representing the end stage of many years of 
accumulation of these pathological changes  [1] . In this 
continuum, mild cognitive impairment (MCI) has been 
considered as a half way condition between normal cogni-
tion and dementia, with an annual rate of progression to 
AD of 15%  [2] . 
 However, not all patients exhibiting MCI will develop 
AD. Therefore, the possibility of identifying individuals 
carrying incipient AD in the MCI population has become 
of utmost importance. Expert consensus groups have 
recommended possible primary biomarker candidates, 
including cerebrospinal fluid (CSF) level of amyloid- β 1-42 
(A β 
1-42
 ), total-tau (t-tau), and phosphorylated tau (p-tau), 
as well as MRI-based assessments of the hippocampus 
and enthorinal cortex and neuropsychological markers of 
memory and non-memory cognitive ability  [3] . 
 There are multiple advantages associated with identi-
fying predictive prognostic indicators of conversion from 
MCI to AD, including the empowerment for patients and 
their families to prepare for the future, and the appropriate 
allocation of early treatment with disease modifying drugs 
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in clinical trials to patients with biomarker indications 
of early conversion to AD whilst not exposing patients 
unlikely of AD conversion to undue risk. Further, the bio-
markers may also be advantageous in prognosis, disease 
progression analysis, treatment development, treatment 
effect monitoring and the study of disease mechanism. 
 CSF biomarkers represent a direct measure of cer-
ebral pathological changes occurring in the AD process. 
Neurofibrillary tangles and amyloid plaques are the prin-
cipal pathologic features of AD and it has been suggested 
that abnormal processing of amyloid precursor protein 
leads to a cascade of events characterized by abnormal 
tau aggregations, synaptic dysfunction, cell death, and 
changes in brain structure  [4] . A β 
1-42
 is a peptide produced 
from the cleavage of the amyloid precursor protein (APP) 
from  α and  γ secretase enzymes. Among different types 
of A β peptides, A β 
1-42
 has been shown to have the higher 
specificity and sensitivity in detecting incipient AD. A β 
1-42
 
in CSF has been proven to be significantly reduced in sub-
jects with AD compared to age-matched controls, by about 
50%  [5] . Tau proteins are also altered; tau becomes hyper-
phosphylated and dissociates from the microtubules in 
AD, causing an increase of CSF total and p-tau  [6] in AD 
subjects. 
 Several studies have shown that the relative risk of 
progression from MCI to AD is increased in patients with 
high baseline tau and p-tau, and low A β 
1-42
 with high 
sensitivity and specificity  [7 – 15] . Following progress in 
research, a working group established by the National 
Institute of Aging in 2011 promoted a revision of the diag-
nostic criteria for AD and MCI, recommending the adop-
tion of CSF biomarkers for the identification of patients 
with  ‘ MCI due to AD ’ in research setting, i.e., patients at 
high risk to develop AD  [16] . 
 The potential of these biomarkers under standardized 
settings has proven to be effective, with a high diagnostic 
performance in a homogeneous mono-center population 
 [17] . However, standardization of these biomarkers is cur-
rently limited and laboratory results often vary  [18, 19] . 
Community studies are therefore required in order to vali-
date the diagnostic accuracy of CSF measures in everyday 
clinical settings. 
 In this study, we explored the utility of CSF biomark-
ers in combination with standard cognitive markers 
to identify MCI patients at risk of conversion to AD and 
other forms of dementia, in a clinical setting over a 2-year 
period. We evaluated the best parameter (or combinations 
of them) for predicting conversion to dementia and time to 
conversion in a general clinical population, transferring 
the research approach with precise patient selection used 
in large cohort studies into a real world clinical scenario. 
 Materials and methods 
 Patients 
 A group of 71 patients with clinical diagnosis of amnestic MCI (sin-
gle domain or multiple domain) recruited from 2007 to 2011 at the 
Memory Clinic, Department of Neurology, New Civil St. Agostino-
Estense Hospital, Modena, Italy, were enrolled into the current study. 
Clinical baseline assessments were performed, including blood tests, 
electrocardiogram (ECG), lumbar puncture, extended medical his-
tory transcription, and neuropsychological evaluation. Neuropsy-
chological assessments included Mini Mental State Examination 
(MMSE), Babcock story recall test, Rey-Osterrieth Figure-delay recall 
test, category and letter fl uency test, attention matrices, Stroop test, 
and Frontal Assessment Battery (FAB). CSF levels of A β 
1-42
 , t-tau and 
p-tau were measured. Subjects were subsequently followed up clini-
cally every 6 months for at least of 24 months (range 24 – 31 months) 
and classifi ed according to whether they had developed AD (MCI-
AD converters) or other dementias (MCI-NAD) or whether they had 
remained stable (sMCI). Baseline diff erences in CSF and neuropsy-
chological biomarkers patterns were investigated, and MCI patients 
were stratifi ed according to eventual diagnoses of conversion to AD 
or other dementia. 
 Among the patient cohort, 23 remained stable (sMCI), 31 
developed AD (MCI-AD), and 17 developed non-AD dementia (i.e., 
frontotemporal dementia, vascular dementia, etc.). In addition, 
according to literature data suggesting that MCI-AD conversion 
appears to be time dependent, and occurs primarily within the ini-
tial 18  months  [20] , we further classifi ed MCI-AD patients as rapid 
(n = 16,   ≤  18 months) or slow (n = 15,  > 18 months) converters. Clinical 
diagnoses of amnestic MCI, probable AD or other dementias were 
made according to published criteria  [21 – 25] . 
 CSF sampling 
 Lumbar punctures were performed in the morning in fasting patients; 
all subjects gave written consent to undergo the lumbar puncture. 
Approximately 7  mL CSF were collected in sterile polypropylene 
tubes and transported to the adjacent laboratory within 30 min. CSF 
was centrifuged for 15 min at 2700  g at controlled room temperature 
and aliquoted in polypropylene storage tubes. To reduce the possibil-
ity of surface adsorption, we aliquoted 400  μ L CSF in 500  μ L tubes. 
If not immediately analyzed, storage tubes were frozen at  – 80  ° C 
awaiting testing. CSF A β 
1-42
 , t-tau, and p-tau 
181
 were measured with 
the ELISA method following manufacturer instructions (Innogenet-
ics, Gent, Belgium). All tests were performed in the same laboratory 
by the same biologist in accordance with recent guidelines  [26] . The 
inter-assay coeffi  cients of variation (CVs) were within 8.6% for t-tau, 
14.1% for A β 
1-42
 , 10.9% for p-tau 
181
 . 
 Analysis of demographical, neuropsychological, and CSF 
data 
 Baseline demographic, neuropsychological, and CSF data were 
analyzed with SPSS 20.0 and STATA11 soft ware using parametric or 
non-parametric tests, as appropriate. First, we investigated baseline 
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(n = 31) 
  MCI-NAD 
(n = 17) 
  sMCI 
(n = 23) 
Gender, F/M   17/14   9/8   13/10
Age, years, mean (SD)   66.2 ( ± 9.4)   66.4 ( ± 7.6)   68.1 ( ± 8.3)
Education, years, mean (SD)   10.4 ( ± 5.7)   9.5 ( ± 4.5)   8.8 ( ± 6.4)
ApoE4 carrier, y/n   10/21   4/13   2/21
MMSE, mean (SD)   25.1 ( ± 3.1)   25.4 ( ± 2.2)   26.8 ( ± 2.3)
Semantic fluency, mean (SD)   31 ( ± 1.9)   35 ( ± 1.7)   38 ( ± 3.6)
Phonemic fluency, mean (SD) c   21 ( ± 11.1)   19 ( ± 13.1)   29 ( ± 9.3)
Babcock story recall, mean (SD)   5.04 ( ± 1.2)   7.9 ( ± 5.2)   6.5 ( ± 5.7)
Rey-Osterrieth Figure-delay recall, mean (SD) b   6.1 ( ± 7.1)   6.9 ( ± 5.2)   11.4 ( ± 5.3)
Frontal Assessment Battery, mean (SD)   12 ( ± 5.1)   12 ( ± 5.9)   13 ( ± 3.8)
Stroop test, errors, mean (SD) a,c   1.0 ( ± 2.1)   6.0 ( ± 7.4)   1.8 ( ± 2.8)
Follow-up, m, mean (SD)   28.2 ( ± 4.5)   25.5 ( ± 1.6)   27.3 ( ± 2.4)
Time of conversion in MCI-AD, months, mean (SD)   18.23 ( ± 7.56)    –    – 
t-tau pg/mL, mean (SD)   466.5 ( ± 292.4)   448.1 ( ± 310.6)   361.6 ( ± 357.3)
P181-tau pg/mL, mean (SD) b   101.4 ( ± 61.5)   69.1 ( ± 40.6)   59.6 ( ± 24.3)
A β 1-42 pg/mL, mean (SD) a,b   442.4 ( ± 114.6)   674.5 ( ± 303.7)   869.9 ( ± 335.4)
A β 1-42/t-tau (ratio) a   1.5 ( ± 0.9)   3.8 ( ± 2.4)   2.4 ( ± 2.9)
A β 1-42/p-tau (ratio) a,b   7.5 ( ± 4.1)   13.8 ( ± 10.08)   15.4 ( ± 10.3) 
 a There is a significant difference between MCI-AD and MCI-NAD (p < 0.05);  b a significant difference between MCI-AD and sMCI (p < 0.05); 
 c a significant difference between sMCI and MCI-NAD (p < 0.05). 
demographic, neuropsychological, and CSF features between groups 
of MCI patients stratifi ed by later diagnoses of conversion to AD, 
other dementia or stable MCI. In particular, ANOVA with post-hoc 
Bonferroni adjustment or Kruskal-Wallis tests followed by Mann-
Whitney tests for pairwise group comparison were used to compare 
sMCI, MCI-AD and MCI-NAD data. Correlation analyses were cal-
culated using Spearman ’ s or Pearson ’ s coeffi  cient, as appropriate. 
Binary logistic regression analyses were performed to distinguish 
MCI-AD from sMCI and MCI-AD from MCI-NAD. The accuracy of these 
models were assessed by area under the curve (AUC) of the receiver 
operating characteristic (ROC) curve. A multinomial logistic regres-
sion analysis was then performed to explore the prediction accu-
racy among the three groups of patients considered together in the 
analysis. A survival analysis (Cox regression model) was performed 
to obtain signifi cant predictors of conversion to AD and of time of 
conversion. Kaplan-Meier survival analysis was used to determine 
median dementia-free survival time. Finally, the MCI-AD subgroup 
was further analyzed according to rapid and slow conversion and an 
independent t-test was used to compare the CSF biomarkers in the 
two groups. 
 Results 
 At baseline, there were no significant differences between 
the groups in terms of age, years of education, gender, 
MMSE, semantic fluency, prose memory, and t-tau. ApoE4 
genotype was prevalent in MCI-AD group compared to 
other groups, but the difference did not reach statistical 
significance after correction for multiple comparisons. 
Significant differences between MCI-AD and MCI-NAD 
were detected in verbal fluency, in Stroop test, in A β 
1-42
 
level, and in A β 
1-42/
 p-tau and A β 
1-42/
 t-tau ratio. In addition, 
MCI-AD showed a significant decrease of CSF A β 
1-42
 level 
and of A β 
1-42/
 p-tau ratio and a significant increase of p-tau 
compared to sMCI ( Table 1 ). 
 Correlation analysis in all MCI groups revealed a sig-
nificant positive correlation between A β 
1-42
 , Babcock Story 
recall test (r = 0.491, p = 0.001) and Rey-Osterrieth Figure-
delay recall test (r = 0.387, p = 0.042;  Figure 1 ). The subgroup 
analysis performed in the three subgroups of MCI patients 
separately (MCI-AD, sMCI, MCI-NAD) revealed that only 
in MCI-AD group there was a significant positive correla-
tion between the three measures; no statistically signifi-
cant correlation was found in sMCI and MCI-NAD. Other 
cognitive measures, A β 
1-42
 or other CSF peptides were not 
correlated. 
 Logistic regression analyses showed that A β 
1-42
 was 
helpful in differentiating MCI converters from sMCI and 
both A β 
1-42
 and p-tau were helpful in discriminating 
between MCI-AD and MCI-NAD. The logistic regression 
considering MCI-AD versus sMCI as diagnostic status and 
MMSE, ApoE status, t-tau, p-tau and A β 
1-42
 as independent 
variables showed that only A β 
1-42
 was helpful in differen-
tiating MCI converters from sMCI ( β = – 0.014, SE = 0.006, 
p = 0.034). This model accounted for between 53% and 
72% of the variance in conversion status, with an overall 
prediction accuracy of 83%. Hosmer and Lemeshow ’ s 
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test indicated a high p-value, confirming the efficiency of 
the model. Sensitivity and specificity of this model were 
95.24% and 80%, respectively (AUC = 0.97 Figure 2B, top), 
the positive predictive value (PPV) was 95.24% and the 
negative predictive value (NPV) was 80%. 
 The logistic regression considering MCI-AD versus 
MCI-NAD as diagnostic status and the MMSE, ApoE status, 
t-tau, p-tau and A β 1-42 as independent variables showed 
that both A β 
1-42
 ( β = – 0.007, SE = 0.002, p = 0.014) and p-tau 
( β = 0.07, SE = 0.032, p = 0.024) were helpful in discriminat-
ing between MCI-AD and MCI-NAD ( Figure 2 A). This model 
accounted for between 37% and 52% of the variance in 
conversion status, with an overall prediction accuracy 
of 84% for non-converters. Hosmer and Lemeshow ’ s test 
indicated a high p-value, confirming the efficiency of the 
model. The sensitivity and specificity of this model were 
85.71% and 77.27%, respectively (AUC = 0.87 Figure 2B, 
bottom), the PPV was 78.26% and the NPV 85%. 
 The logistic regression considering MCI-AD versus 
MCI-NAD plus sMCI as diagnostic status (i.e., conver-
sion to AD vs. all other diagnostic status, both stable MCI 
and MCI converted to other dementia) and MMSE, ApoE 
status, t-tau, p-tau and A β 1-42 as independent variables 
showed that only A β 
1-42
 ( β = – 0.004, SE = 0.002, p = 0.044) 
was helpful in discriminating MCI patients destined to 
convert to AD. This model accounted for between 14% and 
19% of the variance in conversion status, with an overall 
prediction accuracy of 61%. Again efficacy was confirmed 
with a high p-value indicated from Hosmer and Leme-
show ’ s test. The sensitivity and specificity of this model 
were 90.91% and 41.18%, respectively (AUC = 0.62), the 
PPV was 66.67% and the NPV 77.78%. Due to the hetero-
geneous nature of the groups of subjects in this model, 
the specificity and the prediction accuracy significantly 
decreased compared to previous models. The use of 
 A β 
1-42/
 p-tau and A β 
1-42/
 t-tau ratio in these analyses did not 
improve predictability. 
 Finally, the multinomial logistic regression consid-
ering MCI-AD versus sMCI versus MCI-NAD as diagnostic 
status and MMSE, ApoE status, t-tau, p-tau and A β 
1-42
 as 
independent variables showed that A β 
1-42
 was helpful to 
discriminate between AD-MCI and sMCI (relative risk = 1.01, 
p = 0.019), whereas all CSF biomarkers were helpful to dif-
ferentiate AD-MCI from MCI-NAD (relative risk A β 
1-42
 = 1.01, 
p = 0.023; relative risk t-tau = 1.02, p = 0.031; relative risk 
p-tau = 0.87, p = 0.035); in this analysis, the MCI-AD group 
was used as the baseline comparison group. This model 
accounted for between 61% and 71% of the variance in 
conversion status, with an overall prediction accuracy of 
76.7%, which was greater than the proportional by chance 
accuracy criteria of 55.6, suggesting that the model was 
useful. 
 Survival analysis performed with time to AD conver-
sion as a failure covariate showed that MCI patients with 
higher value of CSF A β 
1-42
 had a significantly lower risk of 
AD conversion than individuals with a lower value [hazard 
ratio (HR) = 0.05;  β = – 0.006]. The presence of a lower CSF 
A β 
1-42
 value was associated with a shorter median demen-
tia-free survival (14 months;  Figure 3 ). The cut-off value of 
500 pg/mL for A β 
1-42
 was adopted to distinguish between 
low (i.e., pathological) and high (i.e., normal) CSF levels 
,
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 Figure 1   Correlation analyses between memory performances (visuo-spatial and verbal) and A β 
1-42
 CSF level (pg/mL). 
 Different symbols and colors indicate different diagnostic groups. 
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 In addition, the subgroup analysis between slow and 
rapid converters confirmed the role of A β 
1-42
 in distinguish-
ing between the two groups: rapid converters had lower 
A β 
1-42
 baseline levels as compared to slow converters 
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 Figure 2   Logistic regression results. 
 (A) Scatter plot of CSF biomarkers according to the best logistic regression model for MCI-AD compared to MCI-NAD. (B) On the top, ROC 
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 Figure 3   Survival analysis performed with time of conversion to AD 
as failure covariate in subgroups of MCI patients classified by A β 
1-42
 
CSF level. The cut-off value of 500 pg/mL was adopted according to 
literature data. 
 Discussion 
 MCI is a heterogeneous disorder. MCI patients may 
progress to AD, to other dementing illnesses, (includ-
ing vascular dementia, fronto-temporal dementia and 
Lewy body dementia), or remain relatively stable and 
decline cognitively as in normal aging. Therefore, iden-
tifying biomarkers of incipient AD before symptoms of 
dementia are established has many clinical advantages. 
Among all biological, cognitive, and neuroimaging 
markers, it has been demonstrated that the combined 
pattern of low levels of A β 
1-42
 together with high levels 
of t-tau and p-tau in CSF may accurately differentiate 
MCI patients with incipient AD from those with stable 
MCI  [7] . 
 The aim of the current study was to identify baseline 
levels of classic CSF biomarkers and assess their powers, 
either individually or in combination, in predicting con-
version to AD or other dementias. Patients were monitored 
for at least of 24 months. Patients were then classified 
according to the development of AD (MCI-AD), other 
dementia (MCI-NAD) and those who remained cognitively 
stable (sMCI). 
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 Retrospective analysis of baseline levels identified 
A β 
1-42
 as an important independent biomarker for dif-
ferentiating MCI-AD patients, and as an indicator of 
the time to conversion. A significant reduction of A β 
1-42
 
in MCI-AD compared to both MCI-NAD and sMCI, and a 
significantly lower level of A β 
1-42
 in rapid converters (i.e., 
conversion   ≤  18  months) compared to slow converters 
(i.e., conversion  > 18 months), were found. Additionally, a 
significant increase of p-tau in MCI-AD compared to sMCI 
was evidenced, and t-tau levels were lower in the sMCI 
group compared to MCI-AD and MCI-NAD groups. 
 Prognostic factors and biomarkers of time of conver-
sion are not well recognized in literature. Some studies 
showed an association between time of conversion and 
injury markers, such as CSF p-tau and t-tau  [28, 29] , 
whereas other studies did not find any association  [30] or 
found association with amyloid markers  [31] . In our study, 
A β 
1-42
 CSF value was found to be a predictor not only of 
conversion, but also of time of conversion, whereas we did 
not find this association with neurodegeneration markers 
(i.e., t-tau and p-tau). In a study by Van Rossum and col-
leagues  [28] , the authors found that injury markers but not 
amyloid markers were associated with faster decline from 
MCI to AD, but MCI subjects who went on to convert to AD 
had already at baseline lower MMSE scores compared to 
subjects who did not progress to AD dementia, suggest-
ing that these patients were already at baseline in a more 
advanced stage of the disease, where it is well known 
that markers of neurodegeneration are more useful in 
predicting prognosis than amyloid markers. On the con-
trary, in our study, no significant differences between the 
groups were found in CSF tau level and MMSE at baseline, 
suggesting that our MCI subjects did not differ in terms of 
neurodegenerative process stage at the first visit. Maybe, 
these differences in patient ’ s characteristics and selec-
tion criteria may account for the discrepancies emerged in 
our study compared to previous one in terms of time of 
conversion. In addition, we cannot rule out the presence 
of inter-laboratory differences related to the variability of 
CSF biomarkers assays. 
 Statistical analyses of different combinations of bio-
markers converged to emphasize the central role of A β 
1-42
 
in differentiating the incipient AD type. A β 
1-42
 and p-tau 
were identified through regression and survival models 
as the best predictors for discriminating incipient AD in 
MCI population, in line with previous studies  [7, 9, 10, 15, 
30, 32] . Additionally, A β 
1-42
 was found to be significantly 
correlated with memory performances on cognitive tests. 
This correlation was limited to the MCI-AD group, con-
firming the early and specific involvement of memory in 
preclinical phases of the disease  [33] . Despite this corre-
lation, common cognitive performances were not found 
to be strong predictors of AD conversion in our models. 
These results suggest that CSF biomarkers provide predic-
tive information which cannot be obtained from clinical 
and neuropsychological assessment only. 
 Both binary and multinomial logistic regression 
showed high specificity and sensitivity in detecting 
AD-MCI among sMCI and MCI-NAD separately, whereas 
the level of accuracy decreased for the discrimination of 
incipient AD among more mixed group of patients. As a 
matter of fact, we cannot exclude the presence of Alzhei-
mer ’ s histopathology in patients clinically classified as 
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 Figure 4   On the left, dementia-free survival time (months) plotted against A β 
1-42
 CSF values in MCI-AD group. 
 On the right, subgroup analysis between slow ( > 18 months) and fast ( < 18 months) converters, p < 0.05. 
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high sensitivity but low specificity for the AD-like CSF 
profile  [34] . Unfortunately, we did not have histopatholog-
ical examination to support our results. Maybe a longer 
follow-up could have helped to assess whether patients 
with sMCI eventually progress to AD-type dementia. 
 This study is limited by a relative small sample size 
compared to large research cohort studies. However, the 
study offers insight into the investigation of the role of 
biomarkers in a real  ‘ clinical community setting ’ . The 
advantages associated with the clinical community 
setting are mainly associated with patient selection. 
Large research cohort studies enroll carefully selected 
MCI participants with extensively documented memory 
impairment, and often exclude those with impairment 
arising from other potential causes, resulting in an MCI 
population which doesn ’ t reflect the general clinical 
population. The current study is based on a general clini-
cal patient cohort and confirms the utility of biomark-
ers in detecting AD neuropathological changes in MCI 
patients. Indeed, we included a heterogeneous group of 
MCI patients in the testing of specificity and sensitivity of 
biomarkers in discriminating different neuropathologi-
cal conditions at a preclinical stage. Additional research 
is required to validate the application of CSF biomarkers 
in clinical settings, and procedures for acquisition and 
analysis of samples need to be established for broad scale 
application. 
 Our results suggest that the application of both clini-
cal criteria and CSF biomarkers may reliably predict the 
conversion of MCI to AD, and the time to conversion, even 
in a routine diagnostic work-up. 
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